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Breast cancer is the most common cancer in women. Even though improvements in 
diagnosis and treatment of breast cancer have been made, it is still the most common 
cause of cancer death in women. There is a great need to find biomarkers for early 
detection of the disease and novel drug targets to fight the cancer.  
Cell immortalization is the prerequisite step in tumorigenesis, and identification of the 
biomarkers of immortalized cells may be helpful for early detection of cancer. In this 
thesis, we described identification of 71 immortalization-related proteins. We used 
proteomics and conditionally immortalized human breast epithelial cells. Identified 
proteins showed involvement in immortalization of such functional domains as cell 
proliferation and growth, death, cell assembly and organization, cellular movement, 
cell-to-cell signaling, and cell morphology. Kinase MAP2K3, was identified as down-
regulated in immortalized cells. Overexpression of MAP2K3 in immortal human breast 
epithelial cells was sufficient to induce senescence. p38, p53 and pRB were modulated 
by MAP2K3. We also identified KSR2 as up-regulated in immortalized human breast 
epithelial cells and in human breast tumors.  
Twenty-four proteins affected by hyperthermia of human primary breast epithelial cells 
were also identified. Among the proteins, TGF-β2 was found up-regulated. It induced 
HSP27 expression, and protected cells from cell death. 
Aberrant protein tyrosine nitration has been associated with different diseases, 
including cancer. We explored changes in protein tyrosine nitration during the cell 
cycle, and observed that tyrosine nitration affected a number of cell cycle regulators. 
Cross talk of different regulatory pathways may contribute to the resistance to the anti-
cancer treatment. Targeting of multiple pathways has been regarded as a novel anti-
cancer strategy. We showed that combined action of TGF-1 and EGF involves 
changes in phosphorylation of 47 proteins. We observed that the convergence 
components of TGF-β1 and EGF, e.g., MEK1, CK1, can influence cell proliferation in 
the context of TGF-β1 and EGF signaling. Interestingly, we observed that the strongest 
inhibitory effect of Gefitinib (Iressa), EGFR kinase inhibitor, would be only when both 
EGF and TGF-β are highly active, and MEK1 and CK1 are inhibited. ZAK kinase was 
identified as a convergent target of TGF- and EGF signaling, and was found 
contributing to the positive feedback regulation of cell migration upon combined TGF-
 and EGF action.  
We also studied effects of a long term exposure to EGF and estrogen on tumorigenesis 
of breast epithelial cells. We observed that the long-term exposure to EGF and 17β-
estradiol may affect proliferation rate, colony formation, vessel formation, and stem 
cell features of human breast epithelial cells. 
Thus, our findings provided insights into different mechanisms of tumorigenesis, and 
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1 Introduction  
1.1 Breast Cancer 
Cancer cells divide and grow uncontrollably, forming malignant tumors. It may invade 
surrounding tissues, and metastasize to distant organs. Worldwide, breast cancer is the 
most common invasive cancer in women. In 2008, breast cancer caused 458,503 deaths 
worldwide (13.7% of cancer deaths in women) [1]. 
 
1.1.1 Breast Structure 
The breast lies between the second and sixth ribs, from the sternal edge to the edge of 
the axilla. It is composed of 15-20 lobes that radiate from the nipple. Each lobe is 
surrounded by fat and fibrous connective tissue and is divided into many lobules, also 
called ductal-lobular unit [2]. Lobules end in terminal ductal–lobular units (TDLUs) 
(Figure 1).  It is believed that most breast cancers arise in the TDLU [3]. Histological 
studies of TDLU indicated two major types of cells: inner secretory luminal cells and 
outer contractile myoepithelial cells. The majority of breast carcinomas arise from 
luminal epithelial cells [4]. 
 
Figure 1: Structure of mammary gland. (From Dimri G, et al. [3]. Reproduced with 
permission). 
 
1.1.2 Types of Breast Cancer 
There are several different ways to classify human breast cancer, e.g., histopathology, 
grade, stage, receptor status and DNA arrays. Breast cancer is usually classified 
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primarily by its histological appearance, with division into non-invasive and invasive 
disease. 
Non-invasive Breast Cancer 
Ductal carcinoma in situ (DCIS) is the most common type of noninvasive breast 
cancer, accounting for about 15% of all new breast cancer cases in the U.S [157]. 
Ductal carcinoma in situ refers to an uncontrolled growth of cells that are confined to 
the breast duct.  Lobular carcinoma in situ (LCIS) is characterized by abnormal 
changes in the cells that line the milk-producing lobules, or lobes, of the breast. LCIS 
is much less common and carries slightly less risk of invasive cancer than DCIS.  
Invasive Breast Cancer 
Invasive (infiltrating) ductal carcinoma (IDC) is the most common type of breast 
cancer. About 80% of invasive breast cancers are classified as invasive ductal 
carcinoma [157]. In infiltrating ductal carcinoma, cancer cells have penetrated the 
ductal wall and invaded surrounding breast tissue. The cells may then metastasize to 
other parts of the body through the bloodstream or lymphatic system.  
Invasive (infiltrating) lobular carcinoma (ILC) begins in the milk-producing lobules 
where it extends into the adipose tissue of the breast. It is relatively uncommon, 
comprising about 10% of invasive breast cancers [157]. ILC can also be more 
difficult to detect by mammography [157]. 
Invasive papillary carcinoma is very rare, comprising less than 2% of invasive breast 
cancers [157]. Found predominantly in postmenopausal women, it is characterized by 
nodular densities that may be multiple and are frequently lobulated.  
Phyllodes tumor is a rare ﬁbroepithelial breast neoplasm, which resembles 
ﬁbroadenoma; it accounts for 0.3% to 1% of all primary breast tumors and 2.5% of 
ﬁbroepithelial breast lesions [157]. Phyllodes tumors can be either benign, borderline 
or malignant. Malignant tumors are very rare.  
 
1.1.3 Breast Cancer Detection and Treatment   
Improvement in early detection and treatment decrease the deaths from breast cancer 
over the past two decades [1; 5]. Nowadays, Clinical Breast Exam, Screening 
Mammogram, Breast Self-Examination and Magnetic Resonance Imaging are used 
for detection of breast cancer in clinical practice.  
Five main types of therapies are available for the treatment of breast cancer: surgery, 
radiation therapy, chemotherapy, hormone therapy, and most recently, targeted 
therapy. Most patients are treated with surgery in combination with one or more 
additional therapies for optimal cancer management.  
The primary treatment for breast cancer is surgery to remove the tumor. Radiation 
therapy uses high-energy X-rays or other types of radiation to destroy cancer cells. In 
contrast to radiation therapy and surgery, which are local therapies, chemotherapy is a 
systemic mode of treatment that affects tissues and organs throughout the entire body. 
It uses cytotoxic drugs to kill and prevent the growth of cancer cells. Hormonal 
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therapy has been extensively used in the treatment of patients with ER/PR-positive 
breast cancer. The mechanisms of action of hormonal agents include: 1) Blocking the 
interaction between estrogen and estrogen receptors with selective estrogen receptor 
modulators (SERM), e.g., tamoxifen (Nolvadex), raloxifene (Evista). In 1986, 
tamoxifen was the first drug of its kind approved as monotherapy for the treatment of 
early breast cancer in node-positive, postmenopausal women [6]. 2) Degrading the 
estrogen receptors with selective estrogen receptor down-regulators (SERD). 
Currently, fulvestrant is the only FDA-approved SERD for treatment of breast cancer. 
3)Inhibiting estrogen production with an aromatase inhibitor (AI), e.g., letrozole 
(Femara), anastrazole (Arimidex), and exemestane (Aromasin). These drugs  inhibit 
the action of the aromatase enzyme which converts androgens into estrogens by a 
process called aromatization [7].  
Targeted therapy is directed at specific targets in the body (cellular receptors, proteins 
and enzyme systems) to treat the cancer. Such therapies include monoclonal 
antibodies and small molecules. Trastuzumab (Herceptin), a monoclonal antibody, 
has been used since 1998 to treat certain cases of advanced breast cancer by targeting 
cancer cells overexpressing HER-2/neu, which account approximately 20% to 30% of 
breast cancers [8]. 
 
1.2 Mechanisms of Tumorigenesis 
There are two current ideas that attempt to explain the carcinogenesis. They are the 
clonal evolution model and the cancer stem cell hypothesis (Figure 2).  
 
Figure 2: Two proposed explanations of cancer initiation and progression. (A) Cancer 
stem cells model, and (B) cloncal evolution model. In both (A) and (B), circles 
represent cells (with purple indicating stem or progenitor properties), lightning bolts 
represent mutagenesis, and stars represent mutations. The first star in each circle 
stands for the multiple mutations needed to convert a normal cell to a cancer cell. 
(From Campbell LL., Polyak K. [9]. Reproduced with permission) 
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1.2.1 Clonal Evolution 
Nowell first proposed the clonal evolution model in 1976 [10]. The clonal evolution 
model of carcinogenesis proposes that cancer cells over time acquire various 
combinations of mutations within a tumor and that genetic drift and stepwise natural 
selection for the fittest, most aggressive cells drive tumor progression. According to 
this idea, tumor initiation takes place once multiple mutations occur in a random 
single cell, providing it with a selective growth advantage over adjacent normal cells. 
As the tumor progresses, genetic instability and uncontrolled proliferation allow the 
production of cells with additional mutations and hence new characteristics. These 
cells may leave a large number of offspring by chance, or the new mutations may 
provide a growth advantage over other tumor cells such as resistance to apoptosis.  
Based on this model, in the process of tumorigenesis, abnormal cells display several 
hallmarks that can be distinguished from those of normal counterparts. These include 
immortalization or bypass of senescence, evasion of apoptosis and anti-growth 
signals, growth factor independence, enhanced glycolysis, anchorage-independence, 
resistance to contact inhibition, angiogenesis, degradation of matrix components, 
invasion, migration, etc (Figure 3). 
 
Figure 3: Simplified model of tumorigenesis. 
 
1.2.1.1 Cell Senescence  
Normal somatic cells grown in culture cease to proliferate, senesce, after a finite 
number of divisions. This phenomenon, first described by Hayflick in 1965, is referred 
to as replicative senescence [11]. Epithelial cells have two stages of senescence. The 
first stage, termed M0, is a transient growth plateau that occurs after only a few cell 
divisions [12; 13; 14] . Arrest of epithelial cells in M0 is associated with an increase in 
p16INK4a protein expression, but it is not a consequence of telomere shortening [12; 
13; 14]. Following inactivation of p16INK4a, and in some cell types the inactivation of 
p53, epithelial cells from M0 may continue to proliferate for approximately another 20–
70 population doublings before the second stage of growth arrest, termed M1 or 
agonoescence [13]. Epithelial cell M1 growth arrest is associated with telomere 
shortening [13; 14]. M1-arrested epithelial cells do not express p16INK4a. There are a 
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higher percentage of M1 epithelial cells stained for Annexin-V, a marker of apoptosis, 
than in M0-arrested epithelial cells [12].Senescent cells arrested in G1 phase of the cell 
cycle, remain viable and metabolically active and possess a characteristic 
transcriptional prolife that distinguishes them from quiescent cells. They are 
characterized by expression of β-galactosidase (SA-β-gal) at pH 6 [11], plasminogen 
activator protein 1(PAI-1) overexpression and altered cell morphology characterized by 
giant cell size, increased cytoplasmic granularity and a single large nucleus [15].   
 
1.2.1.2 Cell Immortalization 
In order to form tumors, potential cancer cells must overcome this senescence barrier 
that limits their proliferative potential (Figure 4). This process is called cellular 
immortalization, in which cells escape senescence and acquire an infinite lifespan. Cell 
immortalization is the prerequisite step in human carcinogenesis. It provides the 
opportunity for immortal cells to accumulate sufficient number of genetic mutations, 
and eventually results in promotion of carcinogenesis. It has long been known that loss 
of a key tumor suppressor gene, such as p53, or activation of telomerase contribute to 
spontaneous cellular immortalization [14; 16; 17].  
 
Figure 4: Primary cells reach immortalization after overcoming the senescence barrier 
in culture. Epigenetic changes and/or stochastic mutation/s can lead it to escape from 
senescence. (From Lleonart E M., et al. [18]. Reproduced with permission) 
In vitro immortalization models have been developed using cells immortalized 
chemically, virally or with a biological agent. Mortal cells can be immortalized 
artificially by stabilizing the telomeres by overexpression of hTERT [19], through the 
addition of a chemical mutagen such as aflatoxin B1 [20], or by transduction with viral 
oncogenes such as SV40 T-antigen, adenovirus E1a/E1B and HPV16-E6 or -E7 [21; 
22; 23; 24]. These viral oncogenes act by inhibiting key genes such as the tumor 
suppressor gene proteins p53 and pRB, thus allowing the cell to bypass senescence and 
become immortal [22; 24]. 
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1.2.2 Cancer Stem Cells 
The cancer stem cell hypothesis states that a particular subset of tumor cells with stem 
cell-like properties, called “cancer stem cells” drive tumor initiation, progression, and 
recurrence. By definition, these cells have the abilities to self-renew indefinitely and to 
differentiate, and have characteristics of normal adult stem cells [9]. Cancer stem cells 
are thought to persist as a small fraction of the cells in a tumor. According to the cancer 
stem cell hypothesis, tumor progression is a result of the metastatic spread of these 
cells, and cancer recurrence is caused by their resistance to therapy.  
Breast CSCs have been identified by Al-Hajj et al. in specimens from patients with 
advanced stages of metastatic breast cancer [25]. They demonstrated that cells with a 
specific cell-surface antigen profile (CD44+/CD24−) could successfully establish 
themselves as tumor xenografts. Recent studies have provided definitive evidence for 
the existence of CSC populations within breast cancer cell lines.  
Several techniques have been employed for the characterization of cancer stem cells. 
They include cell surface markers, anchorage-independent cell culture, ALDEFLUOR 
assay, and Side population (SP) technique. 
Expression of cell surface markers 
Expression of cell surface markers has been widely used to isolate stem cells, but the 
choice of marker can greatly vary depending on tissues or species. CD44+/CD24-
/low/lin- is the most common used surface marker in the study of breast stem cells. The 
pioneering study by Al-Hajj and colleagues used breast cancer xenografts to isolate a 
population of cells able to initiate tumors in NOD/SCID mice by the combined 
expression of cell surface markers CD44+/CD24-/low/lin- [25]. As few as 200 of these 
cells generated tumors in NOD/SCID mice whereas 20,000 cells that did not display 
this phenotype failed to do so. The NOD/SCID tumors recapitulated the entire 
heterogeneity of the initial tumor. Furthermore, the CD44+/CD24-/low/lin- cell 
population was able to reinitiate tumors in NOD/SCID mice, and retained this ability 
after serial passages [25]. Thus, these cells, which were able to self-renew, to 
differentiate, and displayed tumorigenic capacity, had CSC features. Flow cytometry 
using cell surface markers have been successfully applied to mice and human samples 
to detect and isolate stem cell populations.  
Anchorage-independent cell culture 
Human mammary stem and progenitor cells were able to survive in suspension and 
produce spherical colonies (mammospheres) composed of both stem and progenitor 
cells. These non-adherent mammospheres were enriched in early progenitor/stem cells 
and able to differentiate along the three mammary epithelial lineages and to clonally 
generate complex functional structures in reconstituted three dimensional culture 
systems as well as reconstitute human normal mammary gland in mice [26].  The 
mammosphere assay, based on the unique property of stem/progenitor cells to survive 
and grow in serum-free suspension, was also successfully used to establish long-term 
cultures enriched in stem/progenitor cells from tumor samples. The mammospheres 
formed in breast tumor showed an increase in side population (SP) fraction and in 
CD44+/CD24-/Lin/low- cells, overexpressed neoangiogenic and cytoprotective factors, 
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expressed the putative stem cell marker OCT4, and displayed high tumorigenic 
potential in NOD/SCID mice [27].   
ALDEFLUOR assay 
The ALDEFLUOR assay is based on the enzymatic activity of aldehyde dehydrogenase 
1 (ALDH1), a detoxifying enzyme responsible for the oxidation of retinol to retinoic 
acid. High ALDH1 activity is associated with several types of murine and human stem 
hematopoietic and neural stem and progenitor cells [28; 29; 30]. This method has been 
recently used with success to isolate stem and progenitors cells from mammary tissues.  
Side population (SP) technique 
The SP technique has been used for many years to isolate both normal and tumor stem 
cells from different organs and species [31; 32]. It is based on the abilities of stem cells 
to exclude vital dyes. Normal and cancer stem cells express transmembrane 
transporters, such as the ATP-binding cassette protein, ABC transporter 
ABCG2/BCRP1 (breast cancer resistance protein 1). These molecules exclude dyes 
such as Hoechst 33342 or Rhodamin 123 from the cells, a property not found in 
differentiated cells that remain positive for the dye. The SP fraction from uncultured 
mammary cells represented ~1% of cells [33]. In contrast, in mammospheres, the SP 
fraction represented 27% of the cells and could generate bi-lineage colonies when 
cultured under differentiating conditions [33]. 
 
1.3 TGF-β Signaling 
1.3.1 TGF-β Superfamily 
Almost all cells secrete TGF-β and have TGF-β receptors. The TGF-β superfamily 
consists of 33 different pleiotropic cytokines that influence cell proliferation, migration, 
and differentiation [34; 35; 36]. It is composed of the TGF-βs (TGF-β1, -β2, and β3, 
which are highly homologous), the bone morphogenic proteins, growth and 
differentiation factors, and activins. Five type II receptors and seven type I receptors 
(also termed activin-receptor like kinases (ALKs) have been identified. Auxilliary co-
receptors have also been identified that regulate access of TGF-β superfamily members 
to signaling receptors [37]. 
TGF-β is synthesized as a latent complex consisting of the mature TGF-β homodimer 
noncovalently linked to the amino-terminal remnant termed latency-associated protein 
(LAP). This small latent complex can be covalently bound to the latent TGF-β binding 
protein (LTBP) and stored in the extracellular matrix (ECM) [38; 39]. In this large 
latent complex, TGF-β is in an inactive conformation and requires processing for the 
activation, release, and to be capable of binding to receptors. Proteolytic cleavage of the 
LTBP and integrin mediated conformational change lead to release mature TGF-β from 
the LAP, generates active TGF-β [40; 41]. Activation of the latent TGF-β complex is 
crucial for regulating TGF-β activity in tissues [42; 43]. 
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1.3.2 TGF-β Signaling 
1.3.2.1 Smad Dependent TGF-β Signaling 
TGF-β family member binds to the Type II receptor and recruits Type I, whereby Type 
II receptor phosphorylates and activates Type I. The Type I receptor, in turn, 
phosphorylates receptor-activated Smads (R-Smads: Smad1, Smad2, Smad3, Smad5, 
and Smad8). Once phosphorylated, R-Smads associate with the co-mediator Smad, 
Smad4, and the heteromeric complex then translocates into the nucleus. In the nucleus, 
Smad complexes activate specific genes through cooperative interactions with other 
DNA-binding and coactivator (or co-repressor) proteins [38; 44; 45] (Figure.5). 
 
Figure 5.  Schematic depicting the Smad and Smad-independent TGF-β signaling 
systems (Modified from Reiner JE., et al. [46]. Reproduced with permission). 
 
1.3.2.2 Smad-Independent TGF-β Signaling 
In addition to its ability to activate Smad2/3, TGF-β also can stimulate Smad2/3-
independent pathways (Figure 5), whose activation and biological activities span all 
cellular compartments, e.g., integrin and Focal Adhesion Signaling, PI3K 
(phosphatidylinositol 3-kinase pathway), AKT, and mTOR, Rho-family GTPases, 
MAP kinase family of dual-specificity protein kinases, which includes ERK1/2 
(extracellular signal-related kinase 1 and 2), JNK (c-Jun N-terminal kinase), eEF1A1, 
p38 MAPK, Nuclear Factor-κB (NF- κB) and Lysyl Oxidase (LOX) [47]. 
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1.3.3 TGF-β and Cancer 
In cancer, TGF-β plays a dual role. In premalignant stages, TGF-β acts as a tumor 
suppressor by inhibition of proliferation of epithelial cells and the induction of 
apoptosis. However, in later stages the epithelial cells become refractory to the growth 
inhibitory properties of TGF-β by mutations in TGF-β receptors or intracellular 
signaling components such as Smads [48]. In addition, tumor cells frequently start to 
secrete high levels of TGF-β [49]. Moreover, TGF-β becomes tumor promoting in a 
paracrine way by stimulating a favorable microenvironment by promoting angiogenesis 
[50], suppression of the immune response [51; 52], and hyperactivation of fibroblasts 
into cancer-associated myofibroblasts [34; 53]. Furthermore, TGF-β also acts on tumor 
cells directly by stimulating an epithelial to mesenchymal transition (EMT). In this 
process, epithelial cells lose their epithelial characteristics and acquire a mesenchymal 
phenotype, which increases their migratory and invasive capacity [36; 54].  
Spontaneous epithelial tumors are significantly increased in mice with mammary 
epithelium-specific expression of dominant negative TβRII [55]. In human neoplastic 
breast lesions, TβRII down-regulation is correlated with progression and aggression 
of both in situ and invasive breast carcinomas [56]. Reduced nuclear levels of 
phosphorylated Smad2/3 are associated with high tumor grades and larger tumor size 
[57]. These data suggest the suppressive role of TβRII in breast tumorigenesis. TβRI 
and TβRIII also play a suppressive role in mammary gland tumorigenesis [37]. In 
breast cancer patients with lymph node and distant metastasis, TGF-β levels in 
plasma are increased and may be predictive of local and distant metastases [46]. TGF-
β signaling also contributes to the resistance of breast cancer cells to DNA-damaging 
chemotherapeutic agents through modulating the MutS homolog 2 (MSH2) 
expression [58]. TGF-β may induce immunosuppression and lead to resistance and 
relapses of breast cancer [59].  
 
1.3.4 Therapeutical Agents Targeting TGF-β Pathway 
The therapeutic potential of the TGF-β signaling pathway is ascribed to its supportive 
function in late stage tumors [60]. A number of approaches to inhibit TGF-β or its 
signaling effectors have shown promise in anticancer treatment. They are generally 
classified into four categories: (1) TGF-β expression inhibition at the translational 
level with antisense oligonucleotides (ASO); (2) blockade of TGF-β interaction with 
its receptors using monoclonal antibodies; (3) small molecule inhibitors; and (4) 
peptide aptamers to Smad proteins [61]. 
 
1.4 EGFR Signaling 
1.4.1 EGFR/erbB Family and Signaling  
Epidermal growth factor (EGF) was first discovered in 1962 from new-born mice by 
Stanley Cohen, as one of the first growth factors that were isolated [62]. The receptor 
for human EGF, EGFR, was purified two decades after EGF was first discovered [63; 
64]. The human EGFR family comprises four closely related receptors: EGFR (HER-1, 
and erbB1), EGFR-2 (HER-2 and erbB2), HER-3/ erbB3, and HER-4/ erbB4, which 
are transmembrane glycoproteins containing an extracellular ligand binding domain 
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and an intracellular receptor tyrosine kinase (RTK) domain [65; 66]. Ligands binding to 
EGFR family include EGF, transforming growth factor (TGF)-α , amphiregulin (AR), 
epiregulin (ER), neuroregulin (NR), heparin-binding EGF, and betacellulin [67; 68]. 
The physiologic downstream signal-transduction pathways modulated by EGFR have 
been well-documented [69; 70]. Following binding of a specific ligand to its 
extracellular domain, EGFR undergoes homodimerisation or heterodimerization (with 
other ErbB family members, including HER2 and HER3) to induce activation of the 
tyrosine kinase (TK) domain. This leads to auto-phosphorylation of critical tyrosine 
residues, which serve as attachment sites for various cellular-docking proteins to 
activate signaling cascades and affect gene transcription (Figure 6) [71; 72]. 
 
Fig. 6 EGF binding to EGFR and subsequent downstream signaling pathways (From 
Zahorowska B., et al. [73]. Reproduced with permission). 
These cascades include the Ras-Raf-MAPK pathway, whereby the activation of Ras 
initiates a multistep phosphorylation cascade and activation of ERK-1/2, which 
regulate cell growth and proliferation [72; 74]. EGFR also relays signals through the 
PI3K to AKT, which directly activates multiple anti-apoptotic factors and also affects 
cell proliferation through the mammalian target of rapamycin (mTOR) pathway [72]. 
The third major pathway involves the signal transducers and activators of 
transcription (STAT), which exerts action on gene transcription and protein 
translation [75; 76].  
 
1.4.2 EGFR/erbB Signaling and Cancer 
Dysregulation of EGFR/erbB pathways can promote tumor processes including 
angiogenesis and metastasis and is associated with poor prognosis in many human 
malignancies [77; 78]. There are several mechanisms that may lead to aberrant 
receptor activation; some of them include receptor overexpression, e.g., 20% to 30% 
of breast cancers are noted to overexpress the Her2 [8; 79], mutations, as well as 
ligand-dependent and -independent mechanisms, which in turn lead to 
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phosphorylation of key tyrosine residues and the recruitment of cytoplasmatic 
substrates. This results in initiating downstream mitogenic events. 
The roles that EGFR/erbB and its ligands play in breast cancer have been a subject of 
intensive study and controversy [80; 81; 82]. Some retrospective 
immunohistochemical studies have indicated that EGFR overexpression in primary 
tumors is an indicator of poor prognosis [82; 83], whereas other similar studies have 
failed to establish such a link [80]. EGFR/erbB is expressed in 18–35% of breast 
cancers but is not overexpressed relative to the normal breast epithelia [81]. 
Overexpression of Her2 has been associated with a more aggressive phenotype with 
decreased survival [84; 85].  
 
1.4.3 Anti-EGFR/erbB Targeted Therapies 
Two major classes of EGFR-targeted therapies have been developed: the anti-ErbB 
monoclonal antibodies (MoAbs) and ErbB-specific TK inhibitors (TKIs). Although 
both classes target the EGFR and HER-2 retrospectively, they differ mechanistically 
and appear to differ in the clinical profile, too [86]. Anti-EGFR MoAbs such as 
cetuximab (ImClone) and panitumumab (Amgen) bind to the extracellular domain of 
EGFR on the surface of tumor cells, thus preventing EGFR ligands from interacting 
and activating the receptor, as well as receptor-ligand internalization. By contrast, 
TKIs such as gefitinib, trade name called Iressa (Astra Zeneca) and erlotinib (Roche, 
Nutley, N.J., USA) block the binding of adenosine triphosphate to the intracellular 
TK domain of EGFR, thereby blocking TK activity and subsequent intracellular 
signaling [87; 88]. In this regard, anti-EGFR MoAbs have now been approved for the 
treatment of advanced colorectal cancer and head and neck carcinomas, and EGFR 
TKIs have been approved for the treatment of advanced non-small-cell lung cancer 
(NSCLC) and pancreatic carcinoma. Further, lapatinib (GlaxoSmithKline) – a dual 
TKI – has been designed for dual suppression of the EGFR (ErbB1) and HER-2 
signaling network and was approved by the US FDA in 2007 for the therapy of breast 
cancer patients treated with first line capecitabine (Roche) [89]. 
 
1.5 Protein Phosphorylation  
Reversible protein phosphorylation is one of the most important and well explored 
post-translational modifications. It is estimated that 30- 50% of the proteins are 
phosphorylated at some time point [90]. Phosphorylation is a major regulatory 
mechanism that controls many basic cellular processes. It may mediate a signal from 
the plasma membrane to the nucleus using a cascade of proteins, by which to regulate 
physiological and pathological processes such as cell growth, proliferation, 
differentiation and apoptosis [91; 92]. Protein phosphorylation may result in 
alteration in protein- protein interactions, protein intracellular localization, and its 
activity [90; 91]. Approximately 30% of drug discovery programs and R&D 
investment by the pharmaceutical industry target protein kinases. Knowledge of 
exactly when and where phosphorylation occurs and the consequences of this 
modification for the protein of interest can lead to an understanding of the detailed 
mechanism of the protein action, and ultimately to the discovery of new drug targets. 
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1.5.1 Detection of Phosphoproteins 
1.5.1.1 Radioactive Labeling of Proteins with 32P Isotope  




P is the oldest, but still one of the most 
sensitive approaches for detection of phosphorylation. Under the appropriate 




P are enzymatically added to the proteins. 
The phosphorylated proteins are then detected by autoradiography. Therefore, 
radioactive labeling detects all types of phosphorylation, and is not specific to only 




P isotopes in 
vitro and in vivo.  
 
1.5.1.2 Phospho-Specific Antibodies 
In 1981, the first documented phospho-antibody was produced in rabbits immunized 
with benzonyl phosphonate conjugated to keyhole limpet hemocyanin (KLH) [93]. 
This antibody broadly recognized proteins containing phosphotyrosine. After that, 
there has been a rapid development in production of the phospho-antibodies. 
Nowadays, a large amount of phospho specific antibodies targeted to different amino 
acids (Ser, Thr, Tyr) at distinct sites in proteins have been produced, and widely used 
in the basic and clinic research [93; 94]. The major decisive factor for selection of 
antibodies is their specificity in detection of a phosphoprotein. Therefore the quality 
of antibodies becomes the key concern on their applications. 
 
1.5.1.3 Phosphoprotein Staining 
Currently, Pro-Q Diamond has increasingly become the first choice of 
phosphoprotein dye [95]. It is a fluorescent dye, and is suitable for the detection of 
phosphoserine-, phosphothreonine-, and phosphotyrosine-containing proteins directly 
in polyacrylamide gels. The sensitivity of ProQ- Diamond staining has been 
improved significantly, and is down to 1- 16 ng. However, it is still considerably less 
sensitive than radioactive methods.  
 
1.5.1.4 Mass Spectrometry (MS) 
Mass spectrometry is one of the most modern techniques for detection of 
phosphorylation. Introduction of MS has significantly advanced the research in 
protein phosphorylation [96]. It may be applied not only for detection of 
phosphorylation, but also identification of phosphorylation sites. Detection of 
phosphorylation by MS has been based on mass spectrum generated by trypsin-
digested peptides. The mass shift of m/z 79.9 or neutral loss m/z 80 or 98 compared 
to its theoretical peptide mass has normally been considered as occurrence of 
phosphorylation. MS provides also a high speed and high sensitivity means for 
detection of phosphorylation.  However, there are several inherent difficulties for the 
analysis of phospho-proteins. Firstly, signals from phosphopeptides are generally 
weaker as compared to non-phosphorylated peptides, as they are negatively charged 
and poorly ionized by MS performed in the positive mode.  Secondly, it can be 
difficult to observe the signals from low-abundance phospho-proteins of interest in 
the high-background of abundant non-phosphorylated proteins. To overcome these 
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drawbacks, enrichment of phophoproteins or phosphopeptides before MS is necessary 
to apply.  
 
1.5.2 Isolation and Enrichment of Phosphorylated Proteins and 
Peptides 
1.5.2.1 Immunoprecipitation 
Phosphospecific antibodies are an efficient tool for enrichment of phosphorylated 
proteins [97]. Antibodies specific to phosphorylated residues are used to 
immunoprecipitate full-length proteins and phosphopeptides. Nowadays, a variety of 
commercial phospho-specifc antibodies with high quality are available, especially 
antibodies to phosphotyrosine.   
 
1.5.2.2 Immobilized Metal Affinity Chromatography (IMAC) 
IMAC [98] is the most frequently used technique for phosphopeptide and 
phosphoprotein enrichment, although it was originally introduced for purification of 
His-tagged proteins. It employs metal chelating compounds which are covalently bound 
to a chromatographic support for the coordination of metal ions.  Phosphorylated 
peptides or proteins are bound to the IMAC stationary phase by electrostatic 
interactions of its negatively charged phosphate group with positively charged metal 
ions bound to the column material via nitriloacetic acid (NTA), iminodiacetic acid 
(IDA), and Tris (carboxymethyl) ethylenediamine (TED) linkers. Immobilized metal 






 were initially shown to bind strongly to proteins with a 







have been demonstrated to show better binding with phosphopeptides.  
 
1.5.2.3 Strong Cation Exchange Chromatography (SCX) 
Strong cation exchange chromatography has been used in the enrichment of 
phosphorylated peptides [99]. This procedure is based on the fact that under acidic 
conditions (pH 2.7) phosphorylated peptides are single positively charged and 
amenable to further separation from nonphosphorylated peptides that usually have a net 
charge of 2+ at low pH. One of the main advantages of this method is that complex 
peptide mixtures can be analyzed directly, since it can be connected directly to LC-
MS/MS for identification or sequencing [100]. However, this strategy does not have 
high specificity and the fractions enriched in phosphopeptides also contain a high 
percentage of contaminants. Therefore, it‟s very common to combine SCX with other 
enrichment methods, i.e. IMAC and TiO2. 
 
1.5.2.4 Titanium Dioxide (TiO2) 
A promising alternative to the use of IMAC for the enrichment of phosphorylated 
peptides was first described by Pinkse et al [101]. The approach is based on the 
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selective interaction of water-soluble phosphates with porous titanium dioxide 
microspheres via binding at the TiO2 surface. Phosphopeptides are trapped in a TiO2 
precolumn under acidic conditions and desorbed under alkaline conditions. An 
increased specificity for phosphopeptides has been reported. Another advantage of this 
approach is that it can be easily coupled with a LC-ESI-MS/MS or LC-MALDI 
MS/MS workflow [102]. Nevertherless, TiO2-based columns may retain 
nonphosphorylated acidic peptides. Peptide loading in 2, 5-dihydroxybenzoic acid 
(DHB) has been described to efficiently reduce the binding of nonphosphorylated 
peptides to TiO2 while retaining high binding affinity for phosphorylated peptides. This 
improved TiO2 procedure was found to be more selective than IMAC.  
 
1.5.2.5 Chemical Modification  
A number of chemical modification strategies were developed in which the phosphate 
group has been replaced with a moiety that is chemically more stable than phosphate. 
One such method employs β-elimination of the phosphate from phosphothreonine or 
phosphoserine and results in the formation of dehydroaminobutyric acid or 
dehydroalanine, respectively. This product can be detected directly using tandem MS 
[103]. Alternatively, Michael addition is used to add a reactive thiol to 
dehydroaminobutyric acid or dehydroalanine to allow attachment of an affinity tag. 
Biotin is a widely used affinity tag and it permits purification of the chemically 
modified (previously phosphorylated) peptides [104]. This chemical modification is 
not applicable to phosphotyrosine residues and suffers from side reactions in which 
nonphosphorylated serine can be tagged. 
 
1.6 Protein Tyrosine nitration (PTN)  
1.6.1 Definition, Characteristics and Sources of Tyrosine Nitration 
Tyrosine nitration is a covalent post-translational protein modification that occurs in 
vivo as a consequence of oxidative stress [105]. Tyrosine is modified in the 3-position 
of the phenolic ring through the addition of a nitro group (NO2) (Figure 7). 
Mitochondria is believed to be the primary locus for protein tyrosine nitration (PTN). 
To nitrate Tyr, nitrogen dioxide ( NO2) reacts with a tyrosyl radical (Tyr ) at diffusion-






) [106] . Once a Tyr  is generated on free or protein-
bound Tyr by reaction with one electron oxidants (reaction 1), NO2 can then react with 
the Tyr  to give NO2Tyr (reaction 2) [107].  







(2)Tyr  + NO2 → NO2Tyr. 
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Figure 7: Formation of 3-nitrotyrosine under the action of a nitrating agent.  
An essential contribution to reaction 2 is NO2, which can be formed both 
enzymatically and non-enzymatically by three primary pathways [107]. Generation of 
peroxynitrite (ONOO−), via the radical–radical reaction of nitric oxide ( NO) with 
superoxide (O2 −), can lead to the formation of NO2. Peroxynitrite is in fast, dynamic 
equilibrium with its conjugated acid, peroxynitrous acid (ONOOH, pKa 6.8), which 
can rapidly undergo homolytic cleavage to yield NO2 and OH [106]. Formation of 
NO2 can also occur via homolytic cleavage of nitrosoperoxocarbonate 
(ONOOCO2−) [108], formed by the reaction of ONOO− and carbon dioxide (CO2) 
[109]. The intermediate ONOOCO2− decays by homolysis of the peroxidic bond to 
form NO2 and carbonate anion radical (CO3 −). Heme peroxidases, such as 
myeloperoxidase (MPO) and eosinophil peroxidase (EPO), contribute to Tyr nitration 
in the presence of hydrogen peroxide (H2O2) by converting NO2−, the primary 
metabolic end product of NO, to NO2 [110]. PTN has been considered to be a stable 
post-translational modification, and there is increasing evidence of an in vivo 
denitration process [111]. 
 
1.6.2 Biological Functions of PTN and PTN-Related Diseases 
There is increasing number of studies focused on PTN on protein activity. It can result 
in a loss, an increase, or no effect on protein function [112; 113]. Oxidative 
modifications have been shown to increase the susceptibility of modified proteins to 
proteolysis. The removal of oxidized proteins can be seen as a defense mechanism 
against the consequences of oxidative stress [114]. An increase in proteolytic 
degradation as a result of exposure of isolated proteins or cells in culture to 
peroxynitrite was observed [114; 115]. PTN might trigger mitochondrial proteolytic 
enzymes [114; 115]. In addition, PTN was also observed to affect cellular function by 
interfering with tyrosine phosphorylation [114; 116]. The shift in pKa of the phenolic 
hydroxyl group due to nitration may be the major cause for this interference (tyrosine 
kinases phosphorylate the neutral phenolic hydroxyl group rather than the negatively 
charged phenolate), but steric hindrance and a distortion of the local protein structure 
may also contribute. The reverse situation has also been observed, in that 
phosphorylation of tyrosine prevents subsequent PTN. Therefore, nitration and 
phosphorylation are two competing chemical reactions at a given tyrosine residue. 
Furethermore, PTN also has been reported contribution to increase the cell 
immunogenity [117]. Endogenous proteins are normally not immunogenic due to 
immunological tolerance. Studies of the recognition of tyrosine nitrated proteins by T-
cells showed that PTN of a tyrosine in a T-cell receptor (TCR) contact position may 
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result in the formation of an immunogenic neoepitope [118; 119]. Moreover, PTN also 
found to be involved in regulation of signaling transduction, e.g. NF-kB, IkB. For 
example, tyrosine nitration triggers dissociation of IkB from NF-kB, this results in the 
activation of a pathway that plays an important role in cancer and inflammation [111; 
120]. 
Currently, accumulating data show a strong link between protein PTN and the 
mechanisms involved in formation of many pathological conditions and diseases: post-
radiation response, acute and chronic inflammation, acute and chronic rejection of the 
allograft, chronic hypoxia, tumor vascularization and microenvironment, 
atherosclerosis, myocardial infarction, chronic obstructive pulmonary disease, diabetes, 
Parkinson‟s disease, Alzheimer‟s disease, and others [121; 122; 123; 124; 125; 126; 
127; 128; 129; 130; 131; 132; 133; 134; 135]. 
 
1.6.3 Detection of Nitrotyrosine 
Several methods have been developed for the detection of nitrotyrosine [136; 137; 138; 
139]. They include antibody- based, mass spectrometry, and fluorogenic tagging.  
Antibody based detection was the first used method for the detection of PTN. 
Currently, nitrotyrosine-directed antibodies have been used to detect protein 
containing nitrotyrosine in cell/tissue homogenate, blood plasma, and tissue section 
[111; 127].  
Mass spectrometric, proteomics-based strategies allow for the identification of 
individual proteins that are nitrated. Two-dimensional (2D) gel electrophoresis based 
proteomics allows to separate a cell/tissue homogenate on the 2D gels, detect the 
nitrated proteins using an anti-NO2Tyr  antibody, and then identifying the peptides 
generated by in-gel proteolytic digestion using matrix-assisted laser desorption 
ionization-time-of-flight (MALDI-TOF) MS. In the case of NO2Tyr containing 
proteins, intact molecules can be measured directly by detecting the corresponding 
covalent modification with a mass difference of + 45. When performing MALDI-
TOF MS analysis, the decomposition products of NO2 involving the loss of one and 
two oxygens (− 16 and − 32 Da, respectively) can also be observed [111]. Shotgun 
based proteomics also has been widely established to identify and quantify the PTN 
[138; 139]. 
The method of fluorogenic tagging involves two reaction steps to convert the 2-
nitrophenol functionality of protein-bound nitrotyrosine chemoselectively into a 
fluorophore [140]. In the first reaction step, the 2-nitrophenol functionality is reduced 
to a 2-aminophenol functionality by sodium dithionite. In the second step, the 2-
aminophenol functionality is converted into a fluorophore by reaction with 
salicylaldehyde and Al3+. This novel histochemical staining selectively detects 2-
nitrophenol, as well as 2-nitrosophenol and 2-aminophenol functionalities. This 
method can detect nitrotyrosine in tissue sections by fluorescence microscopy [107]. 
This method is also applicable for staining protein-bound 2-nitrophenol 
functionalities on western blot membranes in complex biological samples such as 
blood plasma [107]. 
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1.7 Proteomics in Cancer Studies  
1.7.1 Definition and Application in Cancer Research 
The word "proteome" was coined by Wilkins in 1994 [141]. The proteome is the entire 
complement of proteins, including the modifications made to a particular set of 
proteins, produced by an organism or system. This will vary with time and distinct 
surroundings, that a cell or organism undergoes.  
Proteomics is the large-scale study of proteins, particularly their structures and 
functions. In general, proteomics can be classified into three types based on distinct 
applications. (1) Protein expression proteomics, this approach hold promise for 
identifying disease markers (tumor markers) that could be important in early detection, 
diagnosis and in monitoring effectiveness of treatment and eventually leads to the 
design of novel treatments. (2) Functional proteomics, it includes analysis of protein-
protein or protein-DNA/RNA interactions and activitites of proteins. (3) Structural 
proteomics, the main goal of this approach is to map out the structure of protein 
complexes or the proteins present in sub-cellular localization or organelles. Proteomics 
therefore, provide a powerful approach for the analysis of normal and transformed cell 
functions from complex mixtures for the identification of disease specific markers, 
uncovering novel endpoints for the evaluation of chemoprevention agents, and protein 
based drug targets for better treatments [142].  
 
1.7.2 Concepts in Proteomics 
Based on different approaches, proteomics includes gel-based and shotgun 
proteomics (Figure 8). Liquid chromatography of proteins and capillary 
electrophoresis are other two techniques for analysis of full-length proteins, which are 
under strong development. 
 
1.7.2.1 Two-Dimensional Gel (2-DG) -based Proteomics 
Two-dimensional polyacrylamide gel electrophoresis (2D-GE) is a technique that has 
been described for the first time already in 1975 by O'Farrell [143] . Proteins are 
separated according to their isoelectric point by isoelectric focusing in the first 
dimension, and according to their molecular weight in the second dimension. Since 
these two parameters are unrelated, it is possible to obtain an almost uniform 
distribution of protein spots across a two-dimensional gel. The resulting map of 
protein spots can be considered as the protein fingerprint of that sample. Since 
polyacrylamide has the same UV absorbance as proteins, the proteins have to be 
stained in order to make the spots visible on the gel. Coomassie blue staining is the 
most popular protein staining method. It is inexpensive, easy to use and has a wide 
linear range that makes relative quantification easy. However, Coomassie blue 
staining is rather insensitive and a large number of proteins remain undetected using 
this method. In contrast, silver staining has a 20 to 50 times higher detection limit but 
a limited dynamic range [144]. The use of radioactive or fluorescent labels solves the 
problem of lack of linearity in staining intensity. To circumvent the problem of inter 
gel variability, the method of differently labeling the different protein samples and 
separate them on the same gel rather than following the paradigm of one sample – 
 18 
one gel has been developed,  two dimensional difference gel electrophoresis (DIGE) 
[145]. An image is obtained by scanning the gel, and image analysis software enables 
spots of different intensity to be identified by superimposing the images. After 
excising the spots of interest, in situ tryptic digestion and subsequent analysis by 
MALDI-TOF (time-of flight) mass spectrometry, differentially occurring proteins can 
be identified based on the masses of their tryptic fragments. 
 
Figure 8. Schematic description of 2D-GE based and gel-free (shotgun) proteomics. 
 
1.7.2.2 Gel- Free Shotgun Proteomics 
By means of recently developed bottom-up (shotgun) proteomics techniques, 
hydrophobic proteins as well as peptides can be analyzed. Instead of using 2D-PAGE, 
these approaches use multi-dimensional liquid chromatography coupled to tandem 
mass spectrometry to separate and identify the peptides obtained from the enzymatic 
digest of an entire protein extract [149]. It is important to realize that in this approach 
it is not the protein but peptides are separated and subjected to tandem mass 
spectrometric analysis. Mass spectrometric identification of these peptides allows the 
determination of the protein content of the initial sample. Since peptides can be more 
easily separated by liquid chromatography than proteins, a peptide based proteomic 
analysis can be performed much faster and cheaper than a complete gel-based 
analysis. 
   19 
 
2 Present study 
2.1 Aims 
General aims of the thesis are to uncover the mechanism of tumorigenesis of breast 
cancer, and investigate the crosstalk of signaling pathways during cancer development. 
The specific aims for each paper are described as below:  
 To explore the mechanisms of immortalization of breast epithelial cells, by 
proteome profiling of conditionally immortalized primary human breast epithelial cells. 
 To better understand the response to hyperthermia of immortalized primary human 
breast epithelial cells, we performed a proteomics study of these cells cultured at 37°C 
or 39°C. 
 To study the expression of Kinase Suppressor of Ras 2 (KSR2) in human breast 
tumors and its effect on proliferation of breast epithelial cells.  
 To investigate protein tyrosine nitration in the cell cycle. 
 To identify the convergent phosphoproteins of TGF-β1 and EGF signaling 
pathways, systemic analyze their functions, and evaluate their involvement in cell 
proliferation in the context of TGF-β1 and EGF.  
 To explore ZAK, the convergent target of TGF-β1 and EGF, impact on TGF-β1- 
and EGF-dependent regulation of the cell proliferation, migration and apoptosis. 
 To explore mechanisms of tumorigenesis of breast cancer activated upon prolonged 
exposure of cells to EGF and estrogen. Specifically, stemness features of human breast 
epithelial cells.  
 
2.2 Materials and methods 
2.2.1 Materials 
Conditionally immortalized human primary epithelial cells were generated using 
constructs and methods described by O´Hare et al. [143]. Notably, the catalytic subunit 
of human telomerase (hTERT) and a temperature-sensitive mutant of simian virus 40 
large-tumor antigen were used (non-DNA binding non-Bub1 binding thermolabile T 
antigen; [143]). The luminal 226Lts4 and 226LU19 cells were used. Expression of LT 
antigen was confirmed by immunoblotting, and hTERT was monitored by TRAP assay 
(O‟Hare and Jat; unpublished data). 184A1, MCF10A and COS7 cells were obtained 
from ATCC (Manassas, USA), and were cultured in media recommended by ATCC.  
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2.2.2 Two-Dimensional Gel Electrophoresis 
Samples were dissolved in 2-D GE buffer (8 M urea, 4 % CHAPS, 0.5 % DTT, IPG 
buffer, pH 3-10). 100 μg of protein were subjected to isoelectrofocusing (IEF) using 
18 cm linear IPGDry strips with a pH range of 3 to 10 (GE Healthcare, Uppsala, 
Sweden). IEF was performed in an IPGphor (GE Healthcare, Uppsala, Sweden) using 
the following protocol: rehydration, 10 hr; 50 V, 3 hr; 1 000 V, 1 hr; 8 000 V, 10 hr. 
After IEF, strips were equilibrated in 50 mM Tris-HCl, pH 8.8, 6 M urea, 2.0 % SDS, 
30 % glycerol with 1 % DTT for 10 min, and then for 10 min in the same buffer 
containing 4 % iodoacetamide instead of DTT. Equilibrated strips were placed on top 
of 10 % polyacrylamide gels and were fixed with 0.5 % agarose in 62.5 mM Tris-HCl, 
pH 6.8, 0.1 % SDS. SDS-PAGE was performed in a Dalt-Six following the 
manufacturer's recommendations (constant power 50 W, for 6-8 hr; GE Healthcare, 
Uppsala, Sweden). Gels were fixed in 10 % acetic acid and 20 % methanol for 10-12 
hrs. Proteins were detected by silver staining. For each condition we generated at 
least 3 gels using samples from 2 separate experiments.    
 
2.2.3 Gel Image Analysis 
Silver-stained gels were scanned in an ImageScanner with the MagicScan32 software 
and analyzed with calculation of volumes of spots by the ImageMaster 2-D Platinum 
software (GE Healthcare, Uppsala, Sweden). The statistical significance of changes 
was evaluated using the ImageMaster 2-D Platinum Version 6.0 software; embedded in 
the software Student‟s t-test was used. 
 
2.2.4 Mass Spectrometry 
Protein spots were excised from the gels, destained and subjected to in-gel digestion 
with trypsin (modified, sequence grade porcine, Promega, USA), as described earlier 
[150]. Tryptic peptides were concentrated and desalted using microC18 ZipTip‟s 
(Millipore, USA). Peptides were eluted with 65 % acetonitrile, containing the matrix α-
cyano-4-hydroxycinnamic acid, and applied directly onto the metal target and analyzed 
by MALDI TOF MS on a Bruker Ultraflex III (Bruker Daltonics, Bremen, Germany). 
Embedded Bruker software (FlexAnalysis) was used to process the mass spectra. 
Peptide spectra were internally calibrated using autolytic peptides from the trypsin 
(MH+ 842.51, 1045.56, 2211.10 and 3337, 76). To identify proteins, we performed 
searches in the NCBInr sequence database using the ProFound search engine 
(http://65.219.84.5/service/prowl/profound.html). One missed cleavage, alkylation with 
iodoacetamide and partial oxidation of methionine were allowed. Search parameters 
were set on mass tolerance less than 0.1 Da, no limitations of pI, limits of Mr of + 20 
kDa and - 20kDa, as compared to the migration position of a spot in the 2D gel, and 
“mammalian” was selected for species search. Significance of the identification was 
evaluated according to the probability value, „„Z‟‟ value, mass precision of the matched 
peptides and sequence coverage. 
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2.2.5 Systemic Analysis 
Systemic analysis of obtained data was performed using GoMiner 
(http://discover.nci.nih.gov/gominer/), Ingenuity Pathway Analysis (IPA; 
www.ingenuity.com), and Cytoscape tools.  
GoMiner allows classification of identified proteins into biologically coherent 
categories and assesses these categories. 
Functional and pathway analysis was performed using Ingenuity Pathway Analysis 
(IPA), a tool for description of networks and signaling pathways. See 
www.ingenuity.com for detailed description of IPA; IPA can also be evaluated via 
free access trials offered on the www.ingenuity.com. IPA operates with a proprietary 
database which is based on a thorough analysis of reported experimental data. IPA 
considers only those experimental data which have been evaluated by independent 
researchers. This ensures that only confirmed results are taken into consideration for 
building a network. Experimental results which have not been reported by multiple 
laboratories or may have controversial interpretations are not considered by IPA. 
Such stringent selection of experimental data is required to exclude building of 
incorrect dependencies and exclude false-positive relations. Settings for the network 
analysis were taken as recommended by IPA, e.g. the number of connections and 
components between two dataset-defined components. A dataset containing identified 
proteins was uploaded into the Ingenuity Pathway Analysis application, and networks 
were generated. Fischer‟s exact test was used to calculate a p-value determining the 
network connectivity. 
For the analysis with Cytoscape, we generated a network using identified by us 
proteins, MiMi tool and KEGG database. The network was viewed in Cytoscape, 
betweenness was computed by Centiscape tool, and subnetworks were extracted by 
MCODE tool.  
 
2.2.6 Immunoblotting 
Cell lysates were resolved on SDS polyacrylamide gels and transferred onto Hybond P 
membranes (GE Healthcare, Piscataway, NJ). Membranes were blocked with 5 % (w/v) 
BSA and then incubated with a primary antibody against target proteins with dilutions, 
as recommended by the manufacturer, and followed by an HRP-conjugated secondary 
antibody (GE Healthcare, Uppsala, Sweden). The proteins were visualized using 
Luminol Reagents (Santa Cruz Biotechnology Inc.). 
 
2.2.7 Immunohistochemistry 
AccuMax breast cancer arrays (ISU ABXIS Co., Ltd, Seoul, South Korea) were used 
to immunohistochemistry staining. Each array slide contains 45 cases of cancer 
tissues and 4 non-neoplastic tissues. In addition to AccuMax, we used BRC961 
human breast cancer tissue microarrays from US Biomax (US Biomax Inc., Rockville, 
USA). Arrays were stained with primary antibody. Antigen retrieval was performed 
using DakoCytomation target retrieval solution high pH (DAKO, Carpinteria, USA). 
The slides were stained with VECTASTAIN Elite ABC kits (Vector Laboratories Inc., 
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Burlingame, USA) following the manufacturer‟s instruction, counterstained with 
hematoxylin and mounted with Fluoromount G (Southern Biotechnology, 
Birmingham, USA). The stained tissues were photographed using a Leica DFC 
camera and images were acquired with Leica QWin Standard software (Leica 
Microsystems Imaging Solutions Ltd, Cambridge, UK). Intensity of staining was 
evaluated as absent (-), weak (+) and strong (++), when no staining (“absent” or (-)), 
less than 30 % of cells staining and a weak signal (“weak” or (+)), and more than 
90 % of staining and a strong signal (“strong” or (++)) were observed, respectively. 
We evaluated staining in malignant (epithelial) cells of tumors, and epithelial cells of 
normal tissues.  
 
2.2.8 Immunoprecipitation 
The protein concentration was adjusted to 3 mg/mL and the solution was subjected to 
IP with 40 μL of protein agarose-bound primary antibody overnight at 4 °C. The 
protein-bound beads were collected by centrifugation at 12 000 rpm for 1 min and 
washed thoroughly (3 times) with the lysis buffer. The bounded proteins were eluted 
with a buffer containing 100mM DTT, 1% SDS, 50mM Tris/HCl, pH 6.8 for 5min at 
95 °C.  
 
2.2.9 Construct and Transfection 
The construct was made by a polymerase chain reaction (PCR)-directed approach, and 
subcloned in pcDNA3(-) vector (Invitrogen). Site-directed mutagenesis was performed 
with a QuikChange Site-Directed Mutagenesis Kit (Stratagene), and all constructs were 
verified by DNA sequencing. For the generation of stably transfected MCF-7 cells, 
MCF-7 cells were transfected in 6-wells plates using LipofectAMINE 2000 reagent, as 
recommended by the supplier (Invitrogen). After 48 hours transfection, cells were 
transferred to 10-cm petri-dish, and were under selection of 400 μg/ml of G418 for 3 
weeks. Single colonies were picked up, and were under expansion culture for 3 weeks. 
Validation of protein expression in the stable transfected cells was examined by 
immunoblotting with specific antibodies. 
 
2.2.10 Cell Culture and Synchronization 
We used the cell lines as followed: 184A1, MCF10A, MCF7, COS7. All cell lines were 
obtained from ATCC (Manassas, VA). Cells were cultured in media recommended by 
ATCC.  
MCF-7 cells were synchronized at G0/G1 phase by starving the cultured cells for 48 
hrs in DMEM medium supplemented with 0.1% FBS. Synchronization of the MCF-7 
cells at the S phase was followed by methods [151]. In brief, media was replaced from 
proliferating MCF-7 cells with 10% FBS-supplemented medium containing 2 mM 
hydroxyurea (H8627, Sigma-Aldrich) for 16 h. The media was removed and the cells 
were washed three times with PBS solution and incubated in 10% FBS-supplemented 
DMEM for 13 h. Subsequently, hydroxyurea was added from a 500 mM stock solution 
to yield a final concentration of 2 mM hydroxyurea, and the cells were incubated for 
another 13 h. Replacement of the media with one without hydroxyurea permitted the 
cells to progress along the cell cycle in a synchronized fashion.  Cell synchronization in 
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G2/M phase were obtained by incubating exponentially growing cells in complete 
DME medium containing 0.4 μg/ml nocodazole (M1404, Sigma-Aldrich) for 16 h. 
Synchronous progression along the cell cycle was obtained by removing the medium, 
washing with PBS solution and incubating the cells with 10% FBS-supplemented 
medium.  
 
2.2.11 Cell Immortalization, Proliferation, Apoptosis and Migration 
Analysis 
Cell immortalization assay 
Population doubling (PD) rate of cells: 10
5
 cells were plated into each well in 12-well 
plates in triplicates. Every 3 days, cells were trypsinized from plates and cell numbers 
were counted. At each split, 10
5
 cells were reseeded to each well in fresh plates and 
allowed to grow until the next split. Population doublings were calculated with the 
formula PD= log(n2/n1)/log2, where n1 is the number of cells seeded and n2 is the 
number of cells recovered. 
Senescence-associated (SA) β-galactosidase activity assay: SA β -galactosidase activity 
is a marker of senescent cells [11]. After transfection, cells were washed with PBS, 
fixed for 15 min in 3% formaldehyde at room temperature, washed, and incubated at 
37°C overnight with fresh senescence-associated (SA)-β-Gal stain solution: 1 mg/ml X-
Gal in dimethylformamide, 40 mmol/l citric acid and phosphate buffer pH 6.0, 5 
mmol/l potassium ferrocyanide, 5 mmol/l potassium ferricyanide, 150 mmol/l sodium 
chloride, and 2 mmol/l magnesium chloride. After incubation, at least 200 cells in 
several fields were examined and SA β-gal positive cells were counted. Statistical 
significance of observed differences was evaluated with Student‟s t-test. 
Cell proliferation assay 
[
3
H]thymidine incorporation assay  
Cells were seeded in 48-well plates for proliferation assays. Cells were incubated with 
1 μCi/ml of [3H]thymidine for the last 2 h of the 24 h incubation time period. 
Radioactivity incorporated in DNA was measured as described earlier [150]. Statistical 
significance of observed differences was evaluated using Student‟s t-test. 
MTT assay 
Cell proliferation was measured by using CellTiter 96® Non-Radioactive Cell 
Proliferation Assay (Promega, Promega Biotech AB, Stockholm, Sweden). MTT assay 
was performed according to the manufacturer‟s recommendations. Statistical 
significance of observed differences was evaluated using Student‟s t-test. 
Cell apoptosis assays 
Cell apoptosis assays were determined by using Cell Death Detection ELISAPLUS 
(Roche, Germany). Briefly, cell lysates were placed in a streptavidin-coated micro-
plate. A mixture of anti-histone-biotin and anti-DNA-POD was added and incubated 
for 2 h at 25°C. After removal of unbound antibodies by a washing step, POD was 
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determined photometrically at 405 nm with ABTS as substrate. Statistical significance 
of observed differences was evaluated using Student‟s t-test. 
Cell migration assays 
A disposable 96 well chemotaxis chamber (CHEMO-TX 101-8, Chemo TX, USA) was 
utilized to quantify cellular migration. These assays were performed following the 
manufacture‟s recommendation. After the overnight incubation, non migrated cells and 





) and fixed with 1% formaldehyde in PBS buffer. The cells 
migrated through filter were stained with 0.5 % crystal violet. The filters were scanned 
and quantization was performed by using ImageJ software.  
 
2.2.12 Mammosphere Culture 
Cells were trypsinized and mechanically separated and, when necessary, passed 
through 40-μm filters to obtain single cell suspensions that were plated at less than 
10,000 cells per mL in super–low-attachment plates. Number of mammosphere was 




Cells were collected by trypsinization and fixed for at least 30 min in 70% ethanol at 
−20 °C. Then, ethanol was removed, and cells were stained with staining solution (PBS 
supplemented with 0.1% (v/v) sodium citrate, pH 7.4, 0.2 mg/mL RNase A, 20 μg/mL 





 cells were trypsinized to obtain single cell suspension. The cells 
were washed twice in cold PBS + 1% BSA, and subsequently incubated at 4°C with 
either 1:25 diluted CD44-FITC antibody (clone ML5, BD Pharmingen), CD24-APC 
antibody (clone G44-26, BD Pharmingen) in PBS + 1% BSA for 30 minutes in the 
dark. After incubation, the cells were washed twice in cold PBS + 1% BSA and 
resuspended in 400 µl cold PBS + 1% BSA for flow cytometry analysis within 1 hour. 
 
2.2.14 Isolation and Enrichment of Phosphoproteins 
Fe-IMAC technology, reported by Dubrovska and Souchelnytskyi, was used to enrich 
for phosphorylated proteins. Phosphorylation status of proteins was confirmed by 
counter-staining of gels with phosphor-specific fluorescence dye ProQ-Diamond. 
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2.2.15 Metabolic Labeling of Cells with 32P Orthophosphate 
Subconfluent cells were labeled in phosphate-free medium containing 0.5% FBS, 20 
mM HEPES, pH 7.2, and [
32
P]orthophosphate (1.0 mCi/ml). After stimulation with 
10 ng/ml of TGFβ1 or 5 ng/ml EGF alone and in combination for 60 min, the cells 
were washed and lysed in a lysis buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 
0.5% Triton X-100, 50 mM NaF, 10 mM Na4P2O7, 1 mM Na3VO4, 1 mM 
phenylmethylsulfonyl fluoride, 100  units/ml aprotinin). The cell lysates were 
subjected to immunoprecipitation using the anti-ZAK antibody (301-993A, Bethyl); 
immunoprecipitates were then subjected to SDS-PAGE and transferred to a 
nitrocellulose membrane. The radioactivity in the gel was quantified by exposure in a 
Phosphorimager (Molecular Dynamics). 
 
2.3 Results and Discussion 
2.3.1 Paper 1  
Proteome profiling of immortalization-to-senescence transition of human breast 
epithelial cells identified MAP2K3 as a senescence promoting protein which is 
down regulated in human breast cancer 
Up to 70 % of neoplasia in human breast do not give rise to fully malignant tumors. 
Discrimination between benign and malignant neoplasia is of importance for 
selection of treatment. Immortalization is one of the first changes in cells undergoing 
carcinogenic transformation. Identification of biomarkers of immortal cells is 
considered as an efficient way for early detection and prevention of carcinogenesis. 
In paper 1, the goals were to perform proteome profiling of the immortalized cells, 
provide insights into molecular mechanisms of immortalization, and evaluate the 
selected identified proteins as markers of early steps of tumorigenicity. 
In this paper, we used conditionally immortalized primary human breast epithelial 
cells as a model. These cells were generated by expression of hTERT and 
temperature-sensitive mutant (U19tsA58) of simian virus 40 large-tumor (LT) antigen. 
The cellular status of immortal and non-immortal were controlled by temperature. At 
34°C the cells are immortal but when cultured at 39°C, they rapidly cease 
proliferating, and undergo senescence. 
To explore the proteome changes upon immortalization of human breast epithelial 
cells, we generated 2D gels of conditionally immortalized cells cultured at permissive 
34°C and at non-permissive 39°C.  95 proteins were identified as differentially 
expressed. Among them, 71 proteins were immortalization-dependent, while changes 
of 24 of the proteins were observed also in the control temperature-insensitive SV40 
LT cells, i.e. in cells which would remain immortal at the higher temperature.  
We validated changes in expression of 3 proteins selected from the proteins identified 
by proteomics (MAP2K3, CK2α, and KSR2). The immunoblotting assays confirmed 
changes in the protein expression observed in the proteomics study. 
Clustering of identified proteins into functional groups showed that immortalization 
affected proteins involved in cell proliferation and growth, death, cell assembly and 
organization, cellular movement, cell-to-cell signaling and interaction, and cell 
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morphology, as main functional domains Analysis of the network generated by our 
identified proteins and proteins they closely related to suggested possible 
involvement of signalling pathways related to activities of epidermal growth factor 
(EGF), platelet-derived growth factor (PDGF), progesterone, tumor necrosis factor 
(TNF), interferon-γ, and interleukins (IL12, IL29). These regulators have not been 
reported as changed at the early steps of induction of senescence, but as affected later 
upon immortalization-senescence transition of cells. Among intracellular regulators, 
p53, AKT, Erk, HIF1A, H-Ras, NFkB, JNK, p38, PKC, PLCγ, RET and Myc were 
present as highly-connected hubs in the network formed by the identified proteins.  
We selected MAP2K3 for further study, as this kinase has been reported to contribute 
to the oncogenic Ras-induced crisis in cell proliferation and senescence. In our 
proteomics screen, 49% down-regulation of MAP2K3 was observed upon reversal of 
the non-immortal phenotype. Primary human epithelial cells are known to be difficult 
to transfect transiently. These limitations prompted us to use established cultured 
cells for functional studies, as a more efficiently transfectable and controlled model. 
We selected two human breast epithelial cells, 184A1 and MCF10A. These cells are 
immortal, but non-tumorigenic, e.g. do not form tumors. Therefore, 184A1 and 
MCF10A cells may be used as a model for studying early steps of transformation of 
human breast epithelial cells. We calculated the population doubling rate and 
measured senescence-associated (SA) β-galactosidase, to investigate the impacts of 
MAP2K3 on cell senescence. Population doubling rate of MAP2K3-expressing cells 
was decreased already after 3 days, and was halted by day 6, while the control cells 
continued to proliferate. When senescence-associated (SA) β-galactosidase was 
measured, we observed that expression of MAP2K3 strongly increased its activity. 
Both approaches suggested that overexpression of MAP2K3 in 184A1 and MCF10A 
cells resulted in pronounced senescence of cells. Measurement of cell proliferation 
showed that expression of MAP2K3 had an inhibitory effect, which is in agreement 
the increase in the proportion of senescent cells. The network analysis indicated the 
potential involvement of p53, Erk1/2 and p38 in the immortalization-senescence 
transition and regulation of cell proliferation. Therefore, we measured the levels of 
p53, p38, pRB and Erk1/2 in cells transfected with MAP2K3 expression vector. We 
observed that enhanced expression of MAP2K3 led to increase of p53, pRB and p38 
expression, but not Erk1/2. This suggests that p38, p53 and pRB may be involved in 
MAP2K3 activity in human breast epithelial cells, and provide support for further 
mechanistic signalling studies.  
The observations with cultured human breast epithelial cells confirmed the 
proteomics data, and suggested that MAP2K3 may be an important regulator of 
senescence. To explore whether MAP2K3 expression is changed in clinical samples, 
we performed an immunohistochemistry study of human breast cancers using a tissue 
microarray consisting of 30 cases of infiltrating ductal carcinomas (IDC), 8 cases of 
papillary carcinomas, 4 cases of infiltrating lobular carcinomas (ILC), 3 cases of 
phyllodes tumors and of 8 normal breast tissues. Immunohistochemistry staining 
showed significant decrease of MAP2K3 staining in malignant tumor cells, as 
compared to epithelial cells in normal ducts. The decrease in MAP2K3 staining was 
observed independently of TNM gradation, ER, PR and ErbB2 status, indicating that 
MAP2K3 down-regulation may be an early event in carcinogenic transformation.  
In this work, we observed that MAP2K3 was down-regulated in immortalized cells, 
and expression of MAP2K3 in immortal human breast epithelial cells was sufficient 
to induce senescence. This indicates a potential role of MAP2K3 in immortalization. 
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This was supported by our finding that MAP2K3 is down-regulated in cancer, as 
compared to normal human breast epithelial cells. The lack of correlation of 
MAP2K3 down-regulation with TNM gradation, ER, PR, and ErbB2 status indicated 
that the decrease of MAP2K3 expression is an early event in tumorigenesis. Thus, our 
proteomics data provide an insight into the complexity of mechanisms involved in the 
early response to immortalization-senescence transition, and identify additional 
regulatory pathways, as compared to the genomic and transcriptomic profiling. 
MAP2K3 expression analysis confirmed that this kinase may be considered for 
further evaluation as a marker of immortalization of human breast epithelial cells to 
discriminate potentially carcinogenic cells from non-transformed cells of a benign 
neoplasia.  
 
2.3.2 Paper 2  
Proteome profiling of heat-shock of human primary breast epithelial cells, a 
dataset report 
The heat-shock response is a reaction in cells and organisms to elevated temperatures 
(heat shock or heat stress). Cells subjected to heat have to be able to adjust to such a 
shock if they are to survive. The classical responses to heat shock involve the induction 
of heat shock proteins, which include chaperones and proteases, required for protein 
refolding and degradation. Besides mentioned forehead, it‟s believed that many other 
proteins also involved in heat shock response. Relatively little is known about systemic 
features of the response to heat shock in human somatic cells. 
The goals of paper 2 were to perform proteome profiling of heat-shock cells, identify 
the heat shock associated proteins, and explore the possible functions of the identified 
proteins involved in. 
The primary immortalized human breast epithelial cells cultured under 37°C and 39°C 
was used (describe in paper 1). 2-D gels of proteins extracted from immortal cells 
cultured at 37°C and 39°C were generated. On average, 900 protein spots were 
reproducibly observed in each gel. Twenty-four proteins were unambiguously 
identified by MALDI-TOF MS as heat shock related proteins. Among them, fifteen 
proteins were found to be up-regulated and nine proteins were down-regulated in 
response to elevated temperatures. 
To explore biological processes and functions that could be affected by the identified 
proteins, we performed a systemic study using GoMiner, Ingenuity Pathway Analysis 
and Cytoscape. The GoMiner tool clustered the identified proteins based on various 
cellular processes. Involvement of the identified proteins in regulation of cell adhesion, 
cell communication, cell cycle and cell development was predicted. An analysis of 
affected intracellular regulatory mechanisms showed that most of the identified proteins 
were involved in cellular metabolism (TGFB2, ZFP91, HSPB1, PANK1, GLP1R, 
AGPS, ACHE, FTSJ1, PTPRE, CUL5, PRDX2). The other functional domains 
included cell development (ACHE, TGFB2, PRDX2, CUL5, PCOLCE, HSPB1), cell 
communication (PTPRE, ANPP5A, ACHE, ITGA6, GLP1R, TGFb2), cellular 
component organization (ITGA6, TGFB2, ACHE), cell cycle (CUL5, TGFB2), cell 
proliferation (TGFB2, ACHE, CUL5), cell adhesion (ACHE, ITGA6, TGFB2) and in 
cell motility (HSPB1, TGFB2, ACHE).To explore systemic features of the signaling 
mechanisms represented by the identified proteins, we generated networks of 
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interactions between the identified proteins and proteins and genes that may be affected 
by the identified proteins. The network generated by MiMi tool showed 170 nodes, 
including 24 proteins identified by us, and 146 proteins they interacted with. The nodes 
with highest betweenness were TAF1, HSPB1(HSP27), HNF4A, ITGA6, HNF4A, 
GFAP, VIM, MAX and TGFB. 
We validated the changes of expression of HSP27 and TGF-β2 from the heat shock 
response proteins identified by proteomics. For validation, we used breast epithelial 
cells at different stages of transformation, including primary breast epithelial cells, 
tumorigenic breast cells MCF-7 and metastatic breast cancer cells MDA-MB-231. The 
immunoblotting assays showed that HSP27 and TGF-β2 were up-regulated upon 39°C 
hyperthermia in all three breast epithelial cells mentioned above, which confirmed the 
protein expression changes observed in the proteomics study.  
To investigate whether HSP27 expression would be dependent on TGF-β2, we treated 
MCF-7 and MDA-MB-231 cells with TGF-β2 ligand or TGF-β neutralizing pan-
specific antibody. Our data showed that the TGF-β2 induced HSP27 expression, and 
the neutralizing TGF-β antibodies decreased HSP27 expression, as compared to control 
non-treated cells, both at 37°C and at 39°C. A stronger difference was observed with 
cells incubated at 37°C. Thus, our results validated the proteomics data related to 
expression of HSP27 and TGF- β2, and showed that TGF- β2 may be a stimulator of 
HSP27 expression. To explore the roles of TGF-β in the heat shock response, we 
treated cells with TGF-β2 ligand to enhance the effects of TGF-β, or used neutralizing 
pan-specific TGF-β antibody to decrease the effects of endogenous TGF-β. In Cell 
Death Detection ELISAPLUS assay, we observed that TGF-β2 had no significant 
effects on cell apoptosis at 37°C in both MCF-7 and MDA-MB-231 cell. MDA-MB-
231 cells were more sensitive to 39°C heat shock, as compared to MCF-7 cells. MDA-
MB-231 cells had a significantly higher number of apoptotic cells in all three groups 
(control, TGF-β2, Ab-TGF-β), as compared to MCF-7 cells. In agreement with the 
notion that TGF-β2 protects against the cell death-inducing effect of hyperthermia, we 
observed that the addition of TGF-β2 to the cells protected them from cell death by 31 
% and 42 % in TGF-β2-treated MCF-7 and MDA-MB-231 cells at 39°C, as compared 
to the control group and the TGF-β neutralizing antibody-treated group.  
To investigate the role of TGF-β2 on cell proliferation upon heat shock, we performed 
a [
3
H]thymidine incorporation assay. We observed that TGF-β2 inhibited MCF-7 and 
MDA-MB-231 cell proliferation at 37°C. Hyperthermia decreased cell proliferation 
rate in both cell lines to the levels observed for the TGF-β2-treated cells. There was no 
significant difference in the rate of proliferation between the 37°C and the 39°C TGF-
β2-treated groups. 
Thus, systemic analysis predicted a number of functions that may be affected by 
hyperthermia. Our functional studies indicated that TGF-β2 protected cells from cell 
death, and that TGF-β2 stimulated expression of HSP27 in the studied cells. Results 
reported here also provide a list of proteins which can be further explored in the context 
of heat shock response. 
 
2.3.3 Paper 3 
Kinase suppressor of ras 2 is involved in regulation of cell proliferation and is up-
regulated in human invasive ductal carcinomas of breast  
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In paper 1, we identified KSR2 was up-regulated in immortalized human breast 
epithelial cells. In paper 3, we aimed to study the expression of KSR2 in human breast 
tumors and its effect on proliferation of breast epithelial cells. 
KSR2 is a scaffold protein in mitogen-activated protein kinase (MAPK) pathways. To 
explore potential impact of KSR2 on cell proliferation and generic MAPK pathways in 
unbiased way, we used FunCoup tool (http://funcoup.sbc.su.se). The generated network 
showed potential involvement of Raf-1, mitogen-activated kinases 1 and 3 (MAPK1 
and MAPK3), mitogen-activated kinase kinase 1 (MAP2K1) and MAPK scaffold 
protein 1 (MAPKSP1). These molecules provide further links to regulators of the cell 
cycle, p53 and hTERT. A number of other KSR2 interactors involved in regulation of 
the cell cycle were reported, although they have to be validated [152]. Thus, analysis of 
the KSR2-centered network indicated that KSR2 may have an impact on cell 
proliferation. 
To manipulate KSR2 level in cells subjected to cell proliferation assays, we enhanced 
expression of KSR2 by transfecting cells with a specific vector or down-regulated 
KSR2 with a specific siRNA. We studied two human breast epithelial cell lines, 
MCF10A and 184A1, which are both non-tumorigenic and considered to have normal 
phenotype of human breast epithelial cells. These cells can be cultured in vitro, and 
therefore are immortalized. Both cell lines also express KSR2. However, 184A1 cells 
may undergo immortalization crisis, and have lower proliferation potential, as 
compared to MCF10A cells. We observed that down-regulation of KSR2 had a strong 
inhibitory effect on proliferation of both cell lines. KSR2 overexpression had rather 
weak effect on cell proliferation, which was more pronounced for 184A1 cells, but not 
significant for MCF10A cells. This could be explained by the presence of endogenous 
KSR2 in a quantity already sufficient for its normal functions. 
To explore whether KSR2 expression could be altered in breast tumors, we performed 
immunohistochemistry study of human breast tissue microarray. All samples of normal 
breast tissue did not show KSR2 staining. KSR2 staining in tumor samples was 
detected mainly in cytoplasm of cells. No correlations of KSR2 expression with TNM 
gradation of tumors were observed. 
KSR2 plays an important role in activation of various signaling events, with reported 
role in signaling by p38 MAPK and MAP2K3. We found that KSR2 is involved in 
regulation of cell proliferation, and is upregulated in tumor epithelial cells in human 
invasive ductal, invasive lobular and papillary carcinomas of breast. In conclusion, our 
findings provide evidence of a potential role of KSR2 in tumorigenesis, indicating that 
expression of KSR2 may be changed already upon acquisition by cells the ability to 
non-limited proliferation. 
 
2.3.4 Paper 4  
Protein tyrosine nitration in the cell cycle 
Protein tyrosine nitration is a low abundant post-translational modification.  It is a 
potential marker of oxidative/nitrosative stress [153; 154], and associated with many 
physiological and pathological processes such as neurodegenerative diseases, cancer 
and inflammatory diseases [128; 129; 132]. Cell cycle is an important mechanism 
involved in different biological functions. It has been reported that Redox and Reactive 
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nitrogen species (RNS) (nitric oxide (NO) and peroxynitrite (ONOO_)) may affect the 
cell cycle, which are sources of protein tyrosine nitration. However, relatively little is 
known how 3-tyrosine nitration changes in the cell cycle. 
The goals of paper 4 were to identify the 3-tyrosine nitrated proteins at different phases 
of the cell cycle, and explore their possible functions during cell cycle. 
 To enrich for tyrosine nitrated proteins, we used immunoprecipitation with anti-3-NT 
antibodies. We optimized binding, washes, and elution of nitrated proteins from 
antibody beads. Enriched proteins were then analyzed using 1DE, followed by 
Coomassie brilliant blue staining or immunoblotting with antibodies specific for 
nitrotyrosine. Coomassie brilliant blue-stained gels showed that the protein fraction 
eluted with buffer containing 1% SDS has high abundance of proteins. Our trials with 
elution with nitrotyrosine showed that significant quantities of nitrated proteins were 
not released from the beads. The low efficiency of nitrotyrosine elution may be 
attributed to differences between pure nitrated tyrosine and nitrated tyrosine in proteins 
used for generation of the antibody. We estimated that at least 90% of tyrosine nitrated 
proteins could be enriched and recovered using described here protocol.  
We synchronized cells in G0/G1, S and G2/M phases. To monitor cell synchronization, 
we analyzed cells by flow cytometry. MCF-7 cells were synchronized in G0/G1 phase 
by a serum starvation for 48 hours, with 84% of cells in G0/G1 phase. Hydroxyurea 
double block was used to enrich for cells in the S phase, with 77% of cells in S phase, 
and 16 hours nocodazole treatment was used to synchronize mitotic cells, with 88 % of 
cells in G2/M phase.  
To monitor tyrosine nitration of proteins during cell cycle progression, we performed 
immunoblotting of total cell extracts from cells synchronized in different phases of the 
cells cycle. The lowest level of protein tyrosine nitration was observed in cells in the 
G0/G1 phase, as compared to S and G2/M phase. The majority of nitroproteins in 
G0/G1 phase were distributed in molecular range 50 to 75 kDa. The most abundant 
presence of tyrosine nitrated proteins was observed in cells in S phase.  Quantification 
of immunoblots indicated that the distribution of nitrated proteins may be as 1: 10: 7 for 
cells in G0/G1, S and G2/M phases, respectively. This indicates that the total tyrosine 
nitration of proteins changes during the cell cycle, with the highest nitration level in S 
phase.  
To identify tyrosine nitrated proteins, we used described before immuno-enrichment 
protocol, and separated tyrosine nitrated proteins by 2DE. Peptide mass fingerprinting 
with MALDI TOF mass spectrometry was used. We identified 27, 37 and 12 proteins 
in 2D gels representing tyrosine nitration enriched proteins in G0/G1, S and G2/M 
phases, respectively.  
Validation of nitrated proteins was performed by immunoblotting with protein-specific 
antibodies of IP- enriched nitrotyrosine containing proteins from different cell cycle 
phases. Here we examined the nitration status of 3 identified proteins, intergrin-linked 
kinase (ILK), FAST kinase domain 2 (FASKD2) and estrogen receptor 2 (ESR2). We 
observed that ILK was significantly nitrated in G0/G1 phase as compared to S and 
G2/M phase, and the ratio of band intensity was approximately 7: 1: 2 for cells in 
G0/G1: S: G2/M phases.  The level of nitration of FASTKD2 was low at G0/G1 phase, 
increased in S phase, and back to the similar level as G0/G1 phase in G2/M phase. The 
ratio of FASTKD2 nitration in three phases was approximately 1: 3: 1 (G0/G1: S: 
G2/M).  The nitration of ESR2 gradually increased during progression from G0/G1 => 
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S => G2/M, with the ratio of intensity 1: 1.5: 4. Thus, observed tyrosine nitration status 
of ILK, FASKD2 and ESR2 confirmed results obtained by 2DE.  
To gain an insight into functions of the identified proteins, we used Gominer and 
Funcoup analysis tools. We found that the identified proteins may be involved in 
various biological functions. The most abundant functional domains they affected 
included cell growth and proliferation, cell death, metabolism, localization and 
signaling. As we were interested in potential impact of nitrated proteins on the cell 
cycle, we focused on proteins that may regulate cell cycle and cell proliferation.  We 
observed that 7 proteins identified in G0/G1 phase synchronized cells (KHDRBS2, 
ILK, CDKN1A, ZBTB33, STAB1, PRKACG) were earlier described as potential 
regulators of the cell cycle. Among cell proliferation-regulating proteins, 8 proteins 
(RAP1GAP, RIOK3, AHSA1, NSF, CTSS, SCFD1, PCK1, FRMD7) were identified in 
S phase, and 4 nitrated proteins (ZNF777, ZPHP3, VAV3, ITIH4) were indentified in 
synchronized cells in G2/M phase.  
In paper 4, we report identification of proteins enriched for tyrosine nitration in cells 
synchronized in G0/G1, S or G2/M phases of the cell cycle. We identified 27 proteins 
in cells synchronized in G0/G1 phase, 37 proteins in S phase synchronized cells, and 12 
proteins related to G2/M phase. Nineteen of the identified proteins were previously 
described as regulators of cell proliferation. Thus, our data indicate which tyrosine 
nitrated proteins may affect regulation of the cell cycle. 
 
2.3.5 Paper 5  
Network signaling by TGFβ1 and EGF in regulation of the cell proliferation as 
predictor of application of Iressa 
Cell proliferation is controlled by many different positive and negative signals (growth 
factors, cytokines et al). In breast cancer, TGF-β plays dual roles during cancer 
development. In early stage cancer, TGF-β inhibits cell proliferation, and can induce 
cell apoptosis. However, at later stage cancer, it acts as tumor promoter. It promotes 
cell mobility, invasion and metastasis. To understand how the TGF-β and EGF 
signaling interact may provide insights on mechanisms of cancer development, and 
further improve the anti-cancer treatment.  
The goals of paper 5 were to identify convergent phosphoproteins of TGF-β1 and EGF 
signaling. Systemic analyze the identified proteins, with focus on the ones involved in 
regulation of cell proliferation. Interrogate the involvement of the selected proteins in 
regulation of cell proliferation. 
First, we performed cell proliferation assay to test how TGF-β1 and EGF would act on 
MCF7 human breast carcinoma cells. We observed that proliferation of MCF7 human 
breast carcinoma cells was stimulated by EGF, inhibited by TGF-β1, and EGF partially 
reverted inhibitory action of TGF-β1. 
To identify phosphoproteins co-regulated by TGF-β1 and EGF, we performed 
enrichment of phosphoproteins from MCF7 cells using developed by us Fe-IMAC 
method. To confirm phosphorylation status of the separated proteins, the gels were 
counterstained with phosphor-specific ProQ Diamond stain. Image analysis, followed 
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by MALDI-TOF mass spectrometry identified 47 proteins affected by combined action 
of TGF-β1 and EGF, as compared to single treatments and control cells. 
We performed systemic analysis aiming to identify these regulatory mechanisms and 
proteins of key importance for these regulatory mechanisms. Analysis of the networks 
for functional domains affected by the identified proteins showed that cell cycle, DNA 
replication, drug metabolism and regulation of post-translational modifications were the 
top affected molecular processes. Systemic analysis identified CK1 (CSNK1A1) and 
MEK1 (MAP2K1) as two kinases that may have an impact on the TGF-β1 and EGF 
cross-talk. CK1 and MEK1 are kinases. Therefore, to evaluate their impact on cells, 
their kinase activities would have to be targeted primarily. We used U0126 inhibitor of 
MEK1 and D4476 inhibitor of CK1 at 10 μM concentrations suggested as specific by 
numerous studies [155; 156]. To explore whether TGF-β1/EGF cross-talk would affect 
impact of anti-cancer drugs, we treated cells with Iressa. We observed that the U0126 
and D4476 inhibitors alone had no effect on cell proliferation, but when cells were 
treated with TGF-β1, EGF or/and Iressa, the inhibitors modulated cell proliferation 
significantly. We observed the strongest inhibitory effect of Iressa would be only when 
both EGF and TGF-β are highly active, and MEK1 and CK1 are inhibited. 
In this study, we investigated the crosstalk of TGF-β1 and EGF signaling, and 
examined the effects of the common targets in anti-cancer drug, Iressa. Our 
interrogation data indicate also that combination of anti-EGF and anti-TGF-β therapies 
have to include evaluation of the convergence targets, and not only levels of TGF-β, 
EGF and their receptors.  
 
2.3.6 Paper 6  
Role of sterile alpha motif and leucine zipper containing kinase AZK (ZAK) in 
combined signaling by TGF-β1 and EGF 
In paper 5, we identified ZAK kinase as a convergence target in TGF-β1 and EGF 
signaling. ZAK has been reported to regulate cell cycle and apoptosis. There has been 
no exploration of ZAK kinase in the context of TGF-β1 and EGF signaling. Here we 
explored ZAK impact on TGF-β1- and EGF-dependent regulation of the cell 
proliferation, migration and apoptosis. 
ZAK was identified as a convergent target of TGF-1 and EGF signaling. ZAK 
phosphorylation was found to be enhanced by a single treatment of cells with TGF-1 
or with EGF. To validate this observation, we performed 
32
P labelling of the treated 
cells. In agreement with phosphoproteomics data, TGF-1 or EGF-treated cells showed 
higher 
32
P incorporation in ZAK protein, as compared to the control and double treated 
cells. This indicated that TGF-1 or EGF promoted ZAK phosphorylation, while the 
combinatorial treatment showed similar phosphorylation level as in the control cells. 
We generated MCF-7 cells stably transfected with wild-type ZAK kinase, and cells 
stably transfected with kinase-dead ZAK. We observed that the wild-type ZAK over-
expressing cells showed enhanced cell migration upon TGF-β1 or EGF treatment. 
Combined treatment with TGF-β1 and EGF induced maximal increase of the cell 
migration, among all tested conditions. However, the ZAK kinase-inactive mutant 
abrogated the enhancement, which indicated that ZAK kinase activity may be a positive 
regulator of cell migration by the network signaling by TGF-β1 and EGF. Assays of 
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cell proliferation and apoptosis analysis did not show significant differences between 
different treatments in ZAK overexpressing cells. Therefore, ZAK kinase contributes to 
the positive feedback regulation of cell migration upon combined TGF-β1 and EGF 
action. 
 
2.3.7 Paper 7  
Transformation and stemness of human breast epithelial cells exposed to EGF and 
17β-Estradiol 
Exposure of breast epithelial cells to EGF and estrogen may have a strong impact on 
breast tumorigenesis, leading to enhanced incidence of cancer. Anti-EGF and anti-
estrogen therapies are used in treatment of breast cancer. However, knowledge of 
molecular mechanisms governing cell growth upon exposure to EGF and estrogen is 
not fully understood. 
In paper 7, the goals were to explore mechanisms of tumorigenesis activated upon 
prolonged exposure of cells to EGF and estrogen. Specifically, we were interested in an 
impact of the exposure on stemness features of human breast epithelial cells.  
We generated clones of MCF-7 cells exposed to a long-term treatment with EGF and/or 
17β-estradiol, alone or in combination. Clones were selected for their enhanced 
proliferation. We explore cell proliferation, death, migration and invasiveness of the 
clones. Stem cell-like markers were also studied. We observed that the exposure to 
EGF and 17β-estradiol enhanced proliferation rates of MCF-7 cells, as compared to the 
clones of control non-exposed cells. EGF exposure led to enhanced colony formation 
by the cells, while exposure to 17β-estradiol reduced it. Mice tumorigenesis study 
showed no significant differences in tumor take for each clone. However, 17β-
estradiol-exposed clones had a lower tumor volume, as compared to other groups. 
MIB1 staining indicated that EGF and EGF&17β-estradiol clones had higher rate of 
cell proliferation, while estrogen clones had significantly reduced cell proliferation rate, 
when compared to the control group. Vessel score calculated by vWF staining of tumor 
tissue, showed similar response pattern as in proliferation assay. Notably, EGF and 
EGF&17β-estradiol clones had enhanced angiogenesis, while estrogen clones showed 
inhibited vessel formation, as compared to the control group. EGF and EGF&17β-
estradiol clones also showed enhanced breast cancer stem cell features. 
Proliferation rate, colony formation, vessel formation, and stem cell features of human 




Based on the findings in the thesis, we can conclude that 
1  MAP2K3 was down-regulated in immortalized cells, and expression of 
MAP2K3 in immortal human breast epithelial cells was sufficient to induce 
senescence. This indicates a potential role of MAP2K3 in immortalization. 
This was supported by our finding that MAP2K3 was down-regulated in 
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cancer, as compared to normal human breast epithelial cells. The lack of 
correlation of MAP2K3 down-regulation with TNM gradation, ER, PR, and 
ErbB2 status indicated that the decrease of MAP2K3 expression is an early 
event in tumorigenesis. 
2 TGF-β2 and HSP27 were up-regulated in response to hyperthermia. TGF-β2 
stimulated expression of HSP27 in the cells, and protected cells from cell 
death. 
3 KSR2 expression was up-regulated in immortalized human breast epithelial 
cells and in human breast tumors. It may contribute to un-limited cell 
proliferation. 
4 Tyrosine nitrated proteins may affect regulation of the cell cycle. 
5 Combination of anti-EGF and anti-TGF-β therapies has to include evaluation 
of the convergence targets, and not only levels of TGF-β, EGF and their 
receptors.  
6 ZAK kinase contributed to the positive feedback regulation of cell migration 
upon combined TGF-β1 and EGF action. 
7 Proliferation rate, colony formation, vessel formation, and stem cell features 
of human breast epithelial cells were affected after long-term exposure to EGF 
and 17β-estradiol . 
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